RadNet Is Maintained at Overweight by Barclays
Barclays has maintained its Overweight rating on RadNet (RDNT). The specific price target or the rationale behind the maintained rating is not detailed in this snippet.
Assessing RadNet (RDNT) Valuation After Revenue Growth And A Narrower Quarterly Net Loss
RadNet (RDNT) reported first-quarter revenue of US$575.63 million and a narrower net loss of US$33.47 million, despite recent share price declines. The company's valuation is being assessed, with one narrative suggesting a fair value of $89.88 per share due to investments in AI-powered imaging solutions. However, mixed signals on valuation and sentiment suggest investors should review the data carefully, considering risks and alternative metrics like the Price/Sales ratio.
Does Q1 Revenue Beat and Narrower Losses Reshape the Bull Case For RadNet’s AI Strategy (RDNT)?
RadNet (RDNT) reported a strong Q1 2026 with increased revenue of US$575.63 million and narrower net losses, driven by demand for advanced imaging and AI investments. The company's strategy involves expanding outpatient imaging, leveraging AI-enabled workflows, and recent acquisitions to achieve profitability. However, significant spending on digital health and potential pricing pressure in new markets remain key risks for free cash flow.
Earnings call transcript: RadNet Q1 2026 sees revenue growth despite EPS miss
RadNet, Inc. (RDNT) reported record Q1 2026 revenue of $575.63 million, a 22.1% year-over-year increase, driven by strong growth in both its imaging center and digital health segments, despite an EPS miss of -$0.28 against a forecasted -$0.15. The company's stock declined 3.76% post-announcement, but management remains optimistic, raising full-year guidance for imaging center revenue, adjusted EBITDA, and free cash flow due to positive trends and strategic acquisitions. RadNet's digital health segment, DeepHealth, achieved 95% year-over-year ARR growth, reaching $97 million, and continues to integrate AI solutions to transform radiology workflow and enhance productivity.
GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To Know
Shares of GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo fell after the April PPI report indicated accelerating wholesale inflation, with service-sector prices rising at their fastest pace in four years. This creates headwinds for healthcare companies due to increased operating costs and potential regulatory intervention over pricing. Despite the market reaction, the report suggests these pullbacks might offer buying opportunities for high-quality stocks.
RadNet, Inc. Statistics – BMV:RDNT
This page provides key financial statistics and ratios for RadNet, Inc. (BMV:RDNT). It includes data points such as market capitalization, P/E ratio, EPS, ROI, and other financial metrics for annual and quarterly periods, with data spanning from 2006 to 2025. The content is designed as a hub for investors to review the company's valuation, profitability, liquidity, and solvency ratios, as well as per-share metrics.
RadNet Inc stock (US75025X1000): diagnostics specialist in focus after latest quarterly figures
RadNet Inc has reported its latest quarterly figures, prompting investor focus on its imaging strategy. The article highlights how the diagnostic specialist balances growth investments, AI tools, and reimbursement pressures within the US healthcare sector. Key aspects of its business model, revenue drivers, market positioning, and relevance to investors are discussed, emphasizing the company's role in outpatient diagnostic imaging.
Total liabilities & shareholders' equities of RadNet, Inc. – BMV:RDNT
The article presents financial data for RadNet, Inc. (BMV:RDNT), specifically focusing on its total liabilities and shareholders' equities. It indicates that the market for this stock is closed and provides a brief overview of the company's financial information within the TradingView platform.
RadNet stock (US75025X1000): imaging specialist rallies after strong Q1 and upbeat 2025 outlook
RadNet, a US provider of outpatient diagnostic imaging, saw its stock rally after reporting strong Q1 2026 growth and raising its full-year guidance. The company's business model relies on a network of outpatient centers, offering modalities like MRI and CT, and is increasingly integrating AI-supported image analysis for enhanced diagnostics. Investors are focusing on resilient demand for imaging services and RadNet's progress in expanding higher-value AI initiatives, despite competitive pressures and reimbursement uncertainties in the healthcare sector.
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Radnet (RDNT)
Jefferies analysts have issued bullish sentiments on two healthcare companies: Alto Neuroscience, Inc. (ANRO) and Radnet (RDNT). Alto Neuroscience received a Buy rating with a $35.00 price target, and Radnet also got a Buy rating with a target of $95.00, reflecting optimism for both stocks in the sector.
T. Rowe Price (NASDAQ: RDNT) holds 5.4% of RadNet, 4.15M shares
T. Rowe Price Associates, Inc. has reported a 5.4% passive stake in RadNet Inc. (NASDAQ: RDNT), holding 4,154,837 shares as of March 31, 2026. This disclosure was made via a Schedule 13G filing, indicating an investment made for passive purposes rather than to influence control. The filing specifies sole voting power for 4,130,454 shares and sole dispositive power for all 4,154,837 shares, with an explicit disclaimer denying beneficial ownership.
Analysts Have Made A Financial Statement On RadNet, Inc.'s (NASDAQ:RDNT) First-Quarter Report
RadNet, Inc.'s first-quarter results saw shares drop by 9.7% as statutory losses increased significantly, despite revenues beating expectations. Analysts have since revised down their earnings per share forecasts for 2026, though the consensus price target remained largely unchanged, suggesting the earnings decline is not expected to heavily impact valuation. The company is, however, projected to accelerate revenue growth faster than its historical rate and the wider industry.
Analysts Have Made A Financial Statement On RadNet, Inc.'s (NASDAQ:RDNT) First-Quarter Report
RadNet, Inc.'s first-quarter results showed a 9.7% drop in shares, with statutory losses increasing significantly to US$0.43 per share, despite revenues beating expectations. Analysts have revised down their EPS forecasts for 2026, though revenue expectations remain largely unchanged, and the consensus price target was unaffected. The company is still projected to grow faster than the industry, but earnings per share concerns persist.
RadNet Drops 5.9% Amid Sector-Wide Selling
RadNet, Inc. shares fell 5.9% to close at $52.70 due to a broad healthcare sector selloff affecting multiple diagnostic imaging companies, rather than company-specific news. The decline was mirrored by other healthcare stocks, indicating sector-wide weakness potentially driven by macro factors or risk-off sentiment. Investors are now looking for clarity on what triggered this coordinated downturn.
RadNet Earnings: AI Fuels Revenue Beat And Guidance Raise
RadNet (RDNT) reported strong Q1 2026 earnings, with a significant revenue beat driven by a surge in advanced imaging volumes and 51.5% growth in its Digital Health segment, which saw Annual Recurring Revenue nearly double. Despite a bottom-line miss due to aggressive investments in AI-powered digital health, management expressed confidence, raising full-year revenue and Adjusted EBITDA guidance for its core Imaging Center segment. The company is strategically leveraging its cash-generating imaging business to fund rapid expansion in AI-driven healthcare technology, aiming for over $140 million in Digital Health ARR by year-end.
Barclays Maintains RadNet(RDNT.US) With Buy Rating, Maintains Target Price $70
Barclays has reiterated its Buy rating for RadNet (RDNT.US) and maintained its price target of $70. This indicates the firm's continued positive outlook on the company's stock performance and valuation. Investors may consider this an endorsement of RadNet's current standing and future prospects.
RadNet, Inc. (NASDAQ:RDNT) Q1 2026 Earnings Call Transcript
RadNet, Inc. (NASDAQ:RDNT) reported strong Q1 2026 results, with record revenue and adjusted EBITDA despite weather impacts, and subsequently raised its full-year guidance. The company highlighted a significant shift towards advanced imaging, strategic acquisitions in Florida and Indiana, and the accelerating momentum of its Digital Health segment, DeepHealth, which is transforming radiology workflows with AI and cloud-native solutions. DeepHealth ended Q1 2026 with $97 million in annual recurring revenue and is on track to reach over $140 million by year-end, driven by strong commercial wins and ongoing innovation.
RadNet Q1 Net Loss Narrows, Service Revenue Increases
RadNet reported a narrower net loss for the first quarter of 2026, reaching $3.3 million compared to $6.9 million in the prior-year period. The improved financial performance was driven by a 9.2% increase in service revenue, hitting $425.9 million. This growth in revenue highlights a positive trend for the diagnostic imaging services provider.
RadNet (RDNT) grows Q1 2026 revenue to $575.6M while investing heavily in AI acquisitions
RadNet, Inc. reported strong revenue growth in Q1 2026, with total service revenue rising to $575.6 million, but continued to experience net losses due to heavy investments in expansion and AI acquisitions. The company's Digital Health segment, a key area of investment, also saw significant revenue growth but operated at a loss. RadNet acquired AI firm Gleamer SAS for $264.1 million and expanded its imaging center network, reflecting a strategic focus on AI capabilities and market presence despite a net loss of $33.5 million for the quarter.
RadNet posts record Q1 revenue
RadNet, an imaging services provider, reported a record 22.1% increase in total revenue for Q1 2026, reaching $575.6 million, and a reduced net loss. The company's adjusted EBITDA also saw a significant rise, despite an estimated $22 million in lost revenue due to severe winter weather. RadNet has revised its full-year 2026 revenue and free cash flow guidance upwards.
Did Record Q1 Results and New AI JV Just Shift RadNet's (RDNT) Investment Narrative?
RadNet, Inc. reported record Q1 2026 revenue of US$575.63 million and reduced its net loss to US$33.47 million. The company also formed a new AI-powered joint venture with Saint Alphonsus Health System, projected to add US$30 million in annual revenue, which reinforces its strategy of scaling outpatient imaging with AI. While the results and AI ventures support a positive investment narrative, concerns remain about the impact of heavy AI and digital health spending on free cash flow.
LA500 2026: Howard Berger
Howard Berger, co-founder, Chief Executive, and President of RadNet Inc., is featured in the LA500 2026 for his leadership in growing the radiology imaging company into one of the largest networks in the country. RadNet, with about 400 outpatient imaging centers and over $2 billion in revenue, has expanded its focus on AI-driven imaging applications. Notably, its AI subsidiary, Deep Health, recently acquired Gleamer for up to $270 million, positioning RadNet as a global leader in AI solutions for various imaging diagnostics.
Record Q1 growth leads RadNet (NASDAQ: RDNT) to raise 2026 guidance
RadNet (NASDAQ: RDNT) reported record first-quarter 2026 financial results, with total revenue increasing 22.1% to $575.6 million and Adjusted EBITDA rising 36.3% to $63.3 million. This robust performance, driven by significant growth in advanced imaging volumes and its Digital Health segment, led the company to raise its full-year 2026 guidance for Imaging Center revenue, Adjusted EBITDA, and Free Cash Flow. Despite a GAAP net loss, RadNet's financial position remains strong, supported by strategic acquisitions and joint ventures aimed at expanding its AI capabilities and market presence.
RadNet reports Q1 2026 revenue $575.6M, adjusted EBITDA $63.3M and raises 2026 imaging guidance
RadNet reported strong first-quarter 2026 results, with total revenue increasing 22.1% to $575.6 million and Adjusted EBITDA rising 36.3% to $63.3 million. The company raised its full-year 2026 Imaging Center guidance for revenue, Adjusted EBITDA, and free cash flow, driven by increased advanced imaging volumes and growth in its Digital Health segment. Strategic initiatives including the acquisition of Gleamer and a new health system joint venture also contributed to the positive outlook.
RadNet 1Q Loss/Shr 43c >RDNT
RadNet reported a first-quarter loss per share of 43 cents. This financial update indicates the company's performance for the recent quarter.
RadNet: Q1 Earnings Snapshot
RadNet Inc. reported a first-quarter loss of $33.5 million, or 43 cents per share, which was worse than analyst expectations when adjusted for one-time costs at 28 cents per share. Despite the loss, the operator of medical diagnostic imaging centers exceeded revenue forecasts with $575.6 million and anticipates full-year revenue between $2.36 billion and $2.4 billion.
RadNet Reports Record First Quarter Financial Results and
RadNet, Inc. reported record financial results for the first quarter of 2026, with total company revenue increasing by 22.1% to $575.6 million and Adjusted EBITDA rising by 36.3% to $63.3 million. The company also announced an upward revision of its 2026 Imaging Center financial guidance for revenue, Adjusted EBITDA, and Free Cash Flow, driven by strong growth in advanced imaging volumes and strategic acquisitions and partnerships in its Digital Health division. RadNet continues to expand its technology solutions, including AI-powered tools, across its network and through new joint ventures.
RadNet Reports Record First Quarter Financial Results and
RadNet, Inc. reported record first-quarter 2026 financial results, with total company revenue increasing 22.1% to $575.6 million and Adjusted EBITDA rising 36.3% to $63.3 million. The company revised its full-year 2026 Imaging Center financial guidance upwards for revenue, Adjusted EBITDA, and Free Cash Flow, while reaffirming Digital Health guidance ranges. Growth was driven by advanced imaging procedural volumes and the expanding Digital Health division, including the acquisition of Gleamer SAS and new health system partnerships.
A Look At RadNet (RDNT) Valuation After Idaho Joint Venture And Upcoming Q1 Earnings
RadNet (RDNT) has recently entered a joint venture in Idaho and is preparing for its Q1 earnings, yet its share price has seen a 19% decline year-to-date. Despite its AI-focused growth efforts, the stock's valuation is mixed, with some analysts suggesting it is 36% undervalued at $89.88 per share based on future earnings, while others point to a rich P/S ratio compared to the industry average. Investors are advised to review the numbers and consider both the potential rewards and warning signs.
Earnings To Watch: RadNet (RDNT) Reports Q1 Results Tomorrow
RadNet (NASDAQ: RDNT), a diagnostic imaging company, is set to report its Q1 results. The company has a history of exceeding Wall Street's expectations and beat analysts' revenue expectations last quarter, reporting $547.7 million, up 14.8% year on year. Analysts anticipate an 18.6% year-on-year revenue growth for the current quarter, and the stock has seen positive sentiment in the testing & diagnostics services segment, with an average analyst price target of $89.88 against a current share price of $60.52.
Number of shareholders of RadNet, Inc. – GETTEX:PQIA
This article from TradingView focuses on RadNet, Inc. (GETTEX:PQIA), providing an overview of its financial data. The content is primarily a shell for financial information, indicating where users can find details like the number of shareholders.
All eyes on RadNet earnings as imaging growth faces margin test By Investing.com
RadNet Inc. is set to report its first-quarter earnings, with analysts anticipating a loss despite significant revenue growth, fueled by expansion in advanced imaging and digital health services. Investors will be closely monitoring the impact of RadNet's AI integration, same-store sales trends in advanced imaging, and how patient cost pressures affect volumes. Despite recent EPS estimate reductions and price-target cuts from some analysts, Wall Street generally maintains a bullish outlook on the company's long-term prospects.
RadNet Q1 2026 Earnings Preview — May 11, Street Expects -$0.19 EPS
Wall Street anticipates RadNet to report a narrower first-quarter loss with revenue growth. The consensus among six analysts is a loss of $0.19 per share on revenue of $554.7 million, reflecting a significant improvement from the previous year's loss, though analyst sentiment has deteriorated with successive downward revisions. Investors will be keying in on procedure volume trends, comments on payor reimbursement, and any updates on full-year guidance and AI integration during the May 11 earnings release.
RadNet and Saint Alphonsus form Idaho imaging joint venture
RadNet and Saint Alphonsus Health System have partnered to form a joint venture by acquiring Intermountain Medical Imaging, a comprehensive outpatient radiology center with five locations in the Boise, Idaho region. RadNet will manage the operations of these centers, which offer various imaging services including MR, CT, and mammography, and are expected to generate $30 million in annual revenue. The existing Gem State Radiology group will continue to provide professional services and will adopt RadNet's DeepHealth technology platform, integrating AI-supported reporting and workflow automation.
Should RadNet’s (RDNT) Idaho AI Imaging Joint Venture Influence Investor Views on Its Growth Strategy?
RadNet recently formed a joint venture with Saint Alphonsus Health System, acquiring a majority stake in Intermountain Medical Imaging in Idaho. This partnership will integrate RadNet's DeepHealth AI, aiming to improve efficiency and contribute an estimated $30 million in annual revenue. While this deal supports RadNet's AI-driven growth narrative, investors should consider the company's past financial reporting scrutiny and the need for AI investments to translate into clear margin benefits.
(RDNT) as a Liquidity Pulse for Institutional Tactics
This article from Stock Traders Daily provides an AI-driven analysis of Radnet Inc. (NASDAQ: RDNT), highlighting a neutral near and mid-term outlook with a moderate long-term positive bias. It details three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, showing strong long-term support and resistance levels. The analysis emphasizes an exceptional risk-reward setup targeting a 21.0% gain versus a 0.3% risk.
RadNet (RDNT) Expected to Announce Quarterly Earnings on Sunday
RadNet (NASDAQ: RDNT) is anticipated to release its Q1 2026 earnings after market close on Sunday, May 10th, with analysts projecting a loss of ($0.14) EPS on revenue of $557.97 million. The company beat estimates in the prior quarter, reporting $0.23 EPS and $547.71 million in revenue, a 14.8% year-over-year increase. Analysts currently have a "Moderate Buy" consensus rating for RadNet with a price target of $88.14, though insiders have recently sold shares.
B. Riley Securities Maintains RadNet(RDNT.US) With Buy Rating, Cuts Target Price to $83
B. Riley Securities has reiterated its Buy rating for RadNet (RDNT.US) but has reduced the target price from $86 to $83. This adjustment comes despite maintaining a positive outlook on the company.
RadNet forms joint venture with Saint Alphonsus in Idaho By Investing.com
RadNet Inc. (NASDAQ:RDNT) has formed a joint venture with Saint Alphonsus Health System, acquiring a majority equity position in Intermountain Medical Imaging LLC, which includes five outpatient imaging centers in Boise, Idaho. RadNet will manage operations and integrate its DeepHealth technology solutions, projecting approximately $30 million in annual revenue from the venture. This expansion aligns with analyst predictions of profitability for RadNet this year, despite its current valuation appearing overvalued.
RadNet forms joint venture to manage Idaho imaging centers
RadNet has entered into a joint venture with Saint Alphonsus Health System, acquiring a majority equity position in Intermountain Medical Imaging, which operates five outpatient imaging centers in Boise, ID. RadNet will take over the management of these centers, and the existing radiology practice, Gem State Radiology, will continue to provide professional services. All five locations will implement DeepHealth's cloud-first, AI-powered Operations Suite for radiology interpretation, reporting, and operational tools.
RadNet (NasdaqGM:RDNT) Stock Forecast & Analyst Predictions
RadNet (RDNT) is forecast to achieve significant earnings and revenue growth, with EPS expected to increase by 74% annually. Recent developments include the acquisition of Intermountain Medical Imaging and a focus on AI integration, despite some analyst concerns regarding financial transparency and insider selling. Analysts generally maintain bullish price targets, citing outpatient imaging growth, supportive Medicare reimbursement, and AI contributions as key drivers.
Medical imaging service provider RadNet announced a strategic partnership with Saint Alphonsus Regional Medical System to jointly establish a joint venture.
RadNet, a medical imaging service provider, has announced a strategic partnership with Saint Alphonsus Regional Medical System to form a joint venture. This collaboration aims to expand their imaging service network in Idaho, integrating RadNet's outpatient imaging expertise with Saint Alphonsus's healthcare experience. Additionally, RadNet acquired a majority stake in Mountain Imaging's medical imaging business to strengthen its presence in the western United States.
B. Riley Adjusts Price Target on RadNet to $83 From $87, Maintains Buy Rating
B. Riley has adjusted its price target for RadNet (RDNT) to $83, down from the previous $87, while reiterating a "Buy" rating on the stock. The healthcare facilities and services provider also recently expanded its DeepHealth partnership with GE Healthcare to enhance AI-led breast cancer screening and acquired Gleamer to further its radiology AI business. Trading at $56.94, the average analyst target price for RadNet is $90.38.
RadNet expands into its 11th state with new $30M Trinity Health joint venture
RadNet Inc. has expanded into its 11th state by forming a new joint venture with Trinity Health's Saint Alphonsus Health System. This partnership involves jointly operating five imaging facilities in Boise, Idaho, and is expected to generate $30 million in new annual revenue for RadNet. The Los Angeles-based company acquired a majority equity position in Intermountain Medical Imaging LLC to facilitate this expansion.
RadNet and Trinity Health’s Saint Alphonsus Health System Launch a Multi-Site Joint Venture in Boise, Idaho, to Include a Broad Technology Deployment of DeepHealth Solutions
RadNet, Inc. has formed a joint venture with Trinity Health's Saint Alphonsus Health System by acquiring a majority equity position in Intermountain Medical Imaging, LLC in Boise, Idaho. This partnership will integrate DeepHealth's AI-backed digital health solutions across five outpatient imaging centers, aiming to enhance operational efficiency, clinical interpretation, and patient engagement. The venture is expected to generate approximately $30 million in annual revenue for RadNet.
RadNet forms joint venture with Saint Alphonsus in Idaho
RadNet Inc. has formed a joint venture with Saint Alphonsus Health System, acquiring a majority equity position in Intermountain Medical Imaging LLC, encompassing five outpatient imaging centers in Idaho. RadNet will manage operations and implement its DeepHealth technology, projecting approximately $30 million in annual revenue from this expansion. Analysts predict profitability for RadNet this year, despite its stock appearing overvalued according to InvestingPro analysis.
RadNet and Trinity Health’s Saint Alphonsus Health System Launch a Multi-Site Joint Venture in Boise, Idaho, to Include a Broad Technology Deployment of DeepHealth Solutions
RadNet, Inc. has formed a joint venture with Trinity Health’s Saint Alphonsus Health System by acquiring a majority stake in Intermountain Medical Imaging, which operates five outpatient imaging centers in Boise, Idaho. This collaboration will integrate RadNet's DeepHealth solutions, including AI-powered tools for clinical interpretation, reporting, and operational efficiencies, across the five locations. The partnership aims to enhance diagnostic imaging services, improve patient care, and streamline operations, projecting approximately $30 million in annual revenue for RadNet.
RadNet, Inc. Announces Date of its First Quarter 2026 Financial Results Conference Call
RadNet, Inc. announced it will host a conference call on Monday, May 11, 2026, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time) to discuss its first quarter 2026 financial results. Investors can access the call via dial-in numbers or a simultaneous and archived webcast. RadNet is a national leader in diagnostic imaging services and digital health solutions.
RadNet and Trinity Health’s Saint Alphonsus Health System Launch a Multi-Site Joint Venture in Boise, Idaho, to Include a Broad Technology Deployment of DeepHealth Solutions
RadNet, Inc. has formed a joint venture with Trinity Health’s Saint Alphonsus Health System by acquiring a majority equity position in Intermountain Medical Imaging, LLC, which operates five outpatient imaging centers in Boise, Idaho. The partnership will integrate DeepHealth's advanced digital health solutions to improve clinical interpretation, radiologist productivity, operational efficiencies, and patient engagement. This collaboration aims to provide high-quality, cost-effective diagnostic imaging services and is projected to generate $30 million in annual revenue for RadNet.
RadNet Inc (RDNT) Shares Fall 3.5% -- What GF Score of 84 Tells Investors
RadNet Inc (RDNT) shares fell 3.5% to $55.89, leading to a 21.7% year-to-date decline, yet GuruFocus identifies the stock as modestly undervalued with a GF Value™ of $64.75 and assigns a strong GF Score™ of 84/100. Despite its attractive valuation and promising growth potential, the company exhibits lower financial strength and significant insider selling, which suggests caution for investors. RadNet's current forward P/E ratio is also notably lower than its historical median, further supporting the undervaluation claim.
